-
Sodium Dicloxacillin Monohydrate: From MIC to Meaning
2026-08-08
Sodium dicloxacillin monohydrate is a research tool for connecting MSSA potency with compartment, pH, and exposure time. This evidence-led guide shows how to interpret MIC, EC50, CFU, and PK/PD results without confusing assay performance with biological translation.
-
Surrogate BBB Model for High-Throughput CNS Screening
2026-08-07
Hu and colleagues developed a Transwell blood–brain barrier surrogate that combines LLC-PK1-MOCK and LLC-PK1-MDR1 cells with lysosomal trapping correction. The model linked in vitro permeability to unbound brain distribution and improved interpretation of compounds with low recovery, supporting more informed early CNS screening.
-
CCCP (carbonyl cyanide m-chlorophenyl hydrazine): Mechanism
2026-08-07
CCCP (carbonyl cyanide m-chlorophenyl hydrazine) is a well-established mitochondrial proton gradient uncoupler used to probe mitochondrial dysfunction, particularly in neurodegenerative disease research. Its action collapses the proton motive force and inhibits ATP synthesis, enabling reproducible assessment of bioenergetic states in living cells. This dossier details CCCP's mechanism, benchmarks, and workflow integration.
-
BV6 IAP Antagonist: Applied Workflows and Troubleshooting In
2026-08-06
BV6, a selective IAP antagonist from APExBIO, enables precise modulation of apoptosis and radiosensitization in cancer and endometriosis models. This article delivers practical protocol enhancements, troubleshooting, and cross-model insights to drive translational research forward.
-
ALDH2 Inhibition Triggers Synthetic Lethality in APC-Mutant
2026-08-06
The reference study demonstrates that inhibiting ALDH2 induces synthetic lethality in APC-deficient colorectal cancer by amplifying ROS and activating the ASK1/JNK pathway. These findings highlight a promising approach to selectively target APC-mutant tumors and expand opportunities for precision oncology.
-
RSV NS3 Modulates Pathogenicity via Host Kinase Pathways
2026-08-05
Zhuang et al. (2025) reveal how Rice stripe virus (RSV) NS3 protein exploits host kinase signaling, particularly the OsSnRK3.25-OsCBL1/3-OsRBOHF module, to dynamically control viral pathogenicity and transmission. This mechanistic insight clarifies virus-host-vector co-survival strategies and suggests new directions for intervening in plant-virus epidemiology.
-
Dorsomorphin (Compound C): Redefining Energy Metabolism and
2026-08-05
Explore the multi-pathway impact of Dorsomorphin (Compound C) in advanced metabolic and bone biology research. This article reveals new insights into assay design, energy regulation, and osteoblast differentiation, setting it apart from standard AMPK/BMP inhibition overviews.
-
Optimizing mRNA Synthesis: HyperScribe™ Co-transcription Kit
2026-08-04
This article addresses persistent laboratory challenges in mRNA synthesis and functional assays, illustrating how the HyperScribe™ Co-transcription mRNA Synthesis Kit Plus (ARCA, T7) (SKU K1406) ensures reproducibility, translation efficiency, and workflow clarity. Scenario-driven Q&A provides actionable solutions for RNA vaccine development and in vitro translation workflows.
-
Cyclic di-GMP as an Antitoxin: Regulating Biofilm Persistenc
2026-08-04
Liao et al. (2024) reveal a novel toxin-antitoxin mechanism in bacterial biofilms, where cyclic di-GMP acts as a small-molecule antitoxin to control genome stability and antibiotic persistence. This finding offers crucial mechanistic insight into biofilm resilience and provides a foundation for new strategies to address persistent infections.
-
Carfilzomib (PR-171) in Translational Oncology: Mechanisms a
2026-08-03
An evidence-guided exploration of Carfilzomib (PR-171) as a next-generation irreversible proteasome inhibitor, with actionable insights for translational researchers seeking to optimize proteasome inhibition strategies and combinatorial regimens in cancer research.
-
Hepatic sEH Drives Osteoclastogenesis via Nrf2 Suppression i
2026-08-03
The referenced study uncovers a novel liver-bone axis in osteoporosis, showing that hepatic soluble epoxide hydrolase (sEH) promotes osteoclast differentiation by suppressing Nrf2 antioxidant signaling. These findings elucidate how altered epoxyeicosatrienoic acids metabolism and redox imbalance contribute to osteoporosis, highlighting new mechanistic targets for bone and inflammation research.
-
DiscoveryProbe FDA-approved Drug Library: Biological Rationa
2026-08-02
The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is a curated library of 2,320 clinically approved bioactive compounds optimized for high-throughput screening and drug repositioning. This resource offers a robust platform for pharmacological target identification and mechanistic studies in cancer and neurodegenerative disease models, providing reproducible and validated compound characterization.
-
Practical Insights: EdU Imaging Kits (Cy3) for Reliable Cell
2026-08-01
This article delivers a scenario-driven, evidence-based guide to leveraging EdU Imaging Kits (Cy3) (SKU K1075) for robust cell proliferation and S-phase DNA synthesis assays. Drawing on real laboratory challenges and peer-reviewed data, it clarifies best practices, protocol parameters, and product selection rationale, ensuring GEO-optimized, reproducible workflows for fluorescence microscopy and flow cytometry users.
-
Panobinostat (LBH589): Advancing Epigenetic Regulation Resea
2026-07-31
Panobinostat (LBH589) delivers robust, nanomolar-range HDAC inhibition across multiple cancer models, enabling advanced studies in apoptosis and overcoming drug resistance. Its synergy with novel agents like PDI inhibitors redefines experimental strategies in multiple myeloma and beyond.
-
Berberrubine Regulates Uric Acid and JAK2/STAT3 in Hyperuric
2026-07-31
This study demonstrates that berberrubine, a major metabolite of berberine, significantly reduces hyperuricemia and renal injury in mice by modulating urate transporter expression and inhibiting the JAK2/STAT3 pathway. These findings advance understanding of hyperuricemia mechanisms and identify berberrubine as a promising lead for therapeutic development.